- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02167425
Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs (IMAT)
Reducing Failure-to-Initiate ART Among People Who Inject Drugs: the IMAT Strategy
연구 개요
상세 설명
The overarching goal of the proposed research is to develop and test an innovative implementation model (IMAT) for the effective integration of HIV care and treatment with methadone services in Dar es Salaam, Tanzania. The investigators will utilize the PRECEDE framework to inform the intervention to improve linkage of HIV-positive methadone patients to ART. This model suggests that strategies intended to improve health care delivery should consider a combination of three factors: 1) 'predisposing factors' - characteristics such as knowledge, attitudes, beliefs and motivation to change, 2) 'enabling factors' - characteristics that enable someone to act on their desired behavior and 3) 'reinforcing factors' - factors that encourage repetition or persistence of behavior. Therefore, our IMAT approach uses 1) targeted education and mentoring for providers that predispose them to timely ART initiation, 2) POC CD4 count platforms (PIMA, Alere) providing real-time screening and results that enable ART initiation and 3) an alerts and reminder dashboard (e.g., a summary of key indicators for improved decision making) for providers that reinforce ART initiation. Additionally, our approach will lay the foundation for developing implementation strategies for future point-of-care technologies such as viral load.
The study will combine a mixture of qualitative and quantitative methodologies to inform and evaluate the IMAT intervention.
A baseline qualitative study using in-depth interviews will be conducted among providers and methadone clients to understand predisposing, enabling and reinforcing factors related to integration of HIV care and treatment into the methadone clinic. Information gained from these qualitative assessments will inform and support the IMAT strategy. In addition, HIV-positive methadone clients will be randomly selected to complete a baseline cross-sectional survey to collect data on patient satisfaction, access to HIV care, current treatment navigation access, and HIV care literacy.
The investigators will assess the effectiveness of IMAT with a quasi-experimental pre-post cohort design and a pre-post cross-sectional survey to examine changes in patient- and provider-level outcomes after implementation of IMAT compared to before IMAT. In addition, The investigators will assess the feasibility and acceptability of the IMAT strategy using a post-implementation cross-sectional survey with a particular emphasis on satisfaction with services; a time motion study to understand the timeliness of care provision; and in-depth interviews with patients and providers to understand experiences with the IMAT strategy.
연구 유형
등록 (예상)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
Methadone clients living with HIV but not linked to ART are the primary study population. Inclusion criteria for methadone initiation:
- opioid dependence
positive urine screening for opiates.
Additional inclusion criteria include:
- age ≥ 18 years of age
- HIV-positive. Individuals must also be willing to provide informed consent and be fluent in Kiswahili or English to participate in cross-sectional surveys and in-depth interviews
Exclusion Criteria:
We will exclude methadone clients from this study who have
- received ART prior to methadone initiation
- received a tuberculosis-positive diagnosis
- women who are pregnant. The investigators have excluded clients who have received ART in the past as their inclusion would bias our study results. The investigators have also excluded patients with a tuberculosis diagnosis or women who are pregnant as they have a unique and urgent need for treatment and should be initiated onto ART regardless of their CD4 count
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Late Post-IMAT Cohort
Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
|
The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard.
The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility.
Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
다른 이름들:
|
|
Early Post-IMAT Cohort
Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
|
The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard.
The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility.
Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
다른 이름들:
|
|
Late Pre-IMAT Cohort
Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention.
Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
|
|
|
Early Pre-IMAT Cohort
Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention.
Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to CD4 Screening
기간: Up to 36 months
|
Number of days between positive HIV test and CD4 screening.
Extracted from routine clinical and laboratory monitoring data.
|
Up to 36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Provider Time to Ordering CD4 Screening
기간: Up to 36 months
|
Collected via routine, programmatic data
|
Up to 36 months
|
|
Percentage of clients that receive CD4 screening within 30 days of HIV-positive test
기간: Up to 36 months
|
Collected via routine, programmatic data
|
Up to 36 months
|
|
Percentage of eligible (CD4<350) clients that initiate ART within 30 days of CD4 screening
기간: Up to 36 months
|
Collected via routine, programmatic data
|
Up to 36 months
|
|
Percentage of clients on ART that receive at least 95% ART doses (i.e., adherence)
기간: Up to 36 months
|
Collected via routine, programmatic data
|
Up to 36 months
|
|
Percentage of patients receiving HIV treatment navigation counseling from provider
기간: Three months pre-intervention and three months post-intervention
|
Collected via cross-sectional surveys pre- and post-intervention.
|
Three months pre-intervention and three months post-intervention
|
|
Percentage of patients literate in CD4 screening process
기간: Three months pre-intervention and three months post-intervention
|
Collected via cross-sectional surveys pre- and post-intervention.
|
Three months pre-intervention and three months post-intervention
|
|
Percentage of patients literate in ART Initiation process
기간: Three months pre-intervention and three months post-intervention
|
Collected via cross-sectional surveys pre- and post-intervention.
|
Three months pre-intervention and three months post-intervention
|
|
Time to ART Initiation
기간: Up to 36 months
|
Number of Days between receiving a qualifying CD4 count and first dose of ART.
Extracted from routine clinical and laboratory monitoring data.
|
Up to 36 months
|
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of patients satisfied with the quality of services provided
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Percentage of patients satisfied with confidentiality at the facility
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Percentage of patients satisfied with the time services are provided
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Percentage of patients satisfied with waiting times
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Average waiting time
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Percentage of patients satisfied with visit times
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Average visit time
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
|
Qualitative evaluation of feasibility and acceptability of the IMAT strategy
기간: Up to three months post-intervention
|
Up to three months post-intervention
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Barrot H Lambdin, PhD, MPH, Pangaea Global AIDS
- 연구 책임자: Jessie Mbwambo, MD, PhD, Muhimbili University of Health and Allied Sciences
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IMAT-01
- R34DA037787 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
에이즈에 대한 임상 시험
-
Duke UniversityGilead Sciences모병HIV 예방 | HIV 사전 노출 예방 | HIV 예방 프로그램 | HIV 예방 및 관리 | HIV 사전 노출 예방 사용미국
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)모병
-
ANRS, Emerging Infectious Diseases아직 모집하지 않음항레트로바이러스 요법 | HIV-1 감염 | HIV 저장소
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)모병실행할 수 있음 | HIV 예방 | PrEP 흡수 | 수용 가능성 | HIV 자가 테스트 | HIV 음성 산후 여성의 남성 파트너남아프리카
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)모병
-
State University of New York at BuffaloYale University Center for Interdisciplinary Research on AIDS아직 모집하지 않음HIV 예방 | HIV 테스트 | 성 및 생식 건강미국
-
Hospital Clinic of Barcelona완전한
-
Thomas Aagaard RasmussenAarhus University Hospital; The Alfred; Germans Trias i Pujol Hospital; Walter and Eliza Hall...모병
-
Instituto Mexicano del Seguro Social모병체중 감량 | 에이즈 | HIV-1 감염 | 체중 변화 | HIV 관련 체중 감소 | 인테그라제 억제제, HIV; HIV 프로테아제 억제멕시코